Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with 

-rearranged non—small cell lung cancer (NSCLC) and brain metastases.

Approximately 5% of patients with NSCLC have 

Johung explains. Researchers found that patients with the 

 mutation who develop brain metastases have an extended survival, with a median overall survival of 4 years.

This is in comparison to patients with NSCLC with other mutations aside from 

 and develop brain metastases, where the average prognosis is 6 months, Johung says.

View more from the 2015 ASTRO Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ASTRO Annual Meeting

Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged nonâ€“small cell lung cancer and brain metastases. 


Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases